Phase III Teriflunomide adjunct therapy with interferon beta
Phase III Teriflunomide adjunct therapy with interferon beta
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2147 Views
-
Last post by frodo
-
- 0 Replies
- 1222 Views
-
Last post by frodo
-
- 0 Replies
- 1607 Views
-
Last post by NHE
-
- 1 Replies
- 2917 Views
-
Last post by Tif
-
- 2 Replies
- 4135 Views
-
Last post by DIM
-
- 0 Replies
- 2315 Views
-
Last post by NHE
-
- 0 Replies
- 1207 Views
-
Last post by NHE
-
- 0 Replies
- 1790 Views
-
Last post by Petr75
-
- 2 Replies
- 1852 Views
-
Last post by frodo